128 related articles for article (PubMed ID: 35092070)
1. Relationship of interleukin-23 with matrix metalloproteinase-9, pentraxin-3, sleep quality and prostate size in benign prostatic hyperplasia.
Navaneethakannan M; Nandeesha H; Sreenivasan SK
Andrologia; 2022 Jun; 54(5):e14387. PubMed ID: 35092070
[TBL] [Abstract][Full Text] [Related]
2. Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer.
Stallone G; Cormio L; Netti GS; Infante B; Selvaggio O; Fino GD; Ranieri E; Bruno F; Prattichizzo C; Sanguedolce F; Tortorella S; Bufo P; Grandaliano G; Carrieri G
Cancer Res; 2014 Aug; 74(16):4230-8. PubMed ID: 24950910
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
4. Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia.
Arivazhagan J; Nandeesha H; Dorairajan LN; Sreenivasulu K
Aging Male; 2017 Jun; 20(2):115-118. PubMed ID: 28590830
[TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate.
Hashimoto K; Kihira Y; Matuo Y; Usui T
J Urol; 1998 Nov; 160(5):1872-6. PubMed ID: 9783977
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of Low density lipoprotein Receptor-related Protein 1 (LRP-1) and matrix metalloproteinase-9 (MMP-9) in prostate gland: From normal to malignant lesions.
Gilardoni MB; Remedi MM; Oviedo M; Dellavedova T; Sarría JP; Racca L; Dominguez M; Pellizas CG; Donadio AC
Pathol Res Pract; 2017 Jan; 213(1):66-71. PubMed ID: 27931798
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of matrix metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma.
Babichenko II; Andriukhin MI; Pulbere S; Loktev A
Int J Clin Exp Pathol; 2014; 7(12):9090-8. PubMed ID: 25674294
[TBL] [Abstract][Full Text] [Related]
8. [Expressions of interleukin-17 and interleukin-8 in the prostatic tissue of the patients with BPH or BPH with inflammation].
Gao R; Liu QX; Zhou HL; Cao LS; Jiang T; Tang SX; Ding YL
Zhonghua Nan Ke Xue; 2017 Aug; 23(8):697-702. PubMed ID: 29726643
[TBL] [Abstract][Full Text] [Related]
9. Association of Pentraxin-3, Galectin-3 and Matrix Metalloproteinase-9/Timp-1 with Cardiovascular Risk in Renal Disease Patients.
Miljković M; Stefanović A; Bogavac-Stanojević N; Simić-Ogrizović S; Dumić J; Černe D; Jelić-Ivanović Z; Kotur-Stevuljević J
Acta Clin Croat; 2017 Dec; 56(4):673-680. PubMed ID: 29590722
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.
Jung K; Nowak L; Lein M; Priem F; Schnorr D; Loening SA
Int J Cancer; 1997 Apr; 74(2):220-3. PubMed ID: 9133459
[TBL] [Abstract][Full Text] [Related]
11. Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer.
Reis ST; Antunes AA; Pontes-Junior J; Sousa-Canavez JM; Dall'Oglio MF; Piantino CB; Cruz JA; Morais DR; Srougi M; Leite KR
Int Braz J Urol; 2012; 38(2):167-74. PubMed ID: 22555040
[TBL] [Abstract][Full Text] [Related]
12. [Significance of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase and protein Ki-67 in prostate tumors].
Babichenko II; Pul'bere SA; Motin PI; Loktev AV; Abud M
Urologiia; 2014; (5):82-6. PubMed ID: 25807766
[TBL] [Abstract][Full Text] [Related]
13. Association between sleep quality and benign prostate hyperplasia among middle-aged and older men in India.
Ma K; Dong Q
BMC Public Health; 2023 Jun; 23(1):1147. PubMed ID: 37316942
[TBL] [Abstract][Full Text] [Related]
14. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Schenk JM; Kristal AR; Neuhouser ML; Tangen CM; White E; Lin DW; Kratz M; Thompson IM
Am J Epidemiol; 2010 Mar; 171(5):571-82. PubMed ID: 20142396
[TBL] [Abstract][Full Text] [Related]
16. The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican.
Cross NA; Chandrasekharan S; Jokonya N; Fowles A; Hamdy FC; Buttle DJ; Eaton CL
Prostate; 2005 May; 63(3):269-75. PubMed ID: 15599946
[TBL] [Abstract][Full Text] [Related]
17. [Differences in pathological features of histological inflammation between benign prostatic hyperplasia and prostate cancer].
Yang L; Zhao K; Zhang A; Liu LR; Liu ZH; Han P; Wei Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):760-3, 768. PubMed ID: 24325107
[TBL] [Abstract][Full Text] [Related]
18. Hypoadiponectinemia, elevated iron and high-sensitivity C-reactive protein levels and their relation with prostate size in benign prostatic hyperplasia.
Nandeesha H; Eldhose A; Dorairajan LN; Anandhi B
Andrologia; 2017 Sep; 49(7):. PubMed ID: 27658341
[TBL] [Abstract][Full Text] [Related]
19. Expression of NGF, GDNF and MMP-9 in prostate carcinoma.
Baspinar S; Bircan S; Ciris M; Karahan N; Bozkurt KK
Pathol Res Pract; 2017 May; 213(5):483-489. PubMed ID: 28237042
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia.
Liu L; Li Q; Han P; Li X; Zeng H; Zhu Y; Wei Q
Urology; 2009 Aug; 74(2):340-4. PubMed ID: 19464042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
